Navigation Links
Orthopedic Development Corporation's TruFUSE(R) Procedure Tops 1,750 Patients in First Year
Date:9/24/2007

CLEARWATER, Fla., Sept. 24 /PRNewswire/ -- Orthopedic Development Corporation, parent company to minSURG Corporation announced today that over 1,750 patients have received the TruFUSE posterior fusion procedure since its introduction last year. TruFUSE, one of the first intermediate surgical solutions to treat intractable back pain, has been in limited distribution.

The TruFUSE technique uses two small cork-shaped dowels made of human bone, called allografts, to stabilize vertebrae, and is used mostly in the lower, or lumbar, spine. The dowels are inserted using an entirely percutaneous or minimally invasive, minimally destructive technique between facet joints in the back to stop movement and pain. The TruFUSE technique is one of the first intermediate surgical options to fill the large void between traditional non-surgical back pain management and major spine fusion surgery. Two dowels are used to fuse one vertebra.

TruFUSE has been used on select patients since March 2006, and went into limited distribution in August 2006. With 30 distributors and over 100 hospital approvals and active surgeons, minSURG is preparing a broad market launch and expects to train and certify an additional 400 to 500 surgeons before the end of the year.

James Doulgeris, MinSURG's president and CEO, said, "TruFUSE represents a new, intermediate surgical option for many chronic back pain sufferers where there was none before. We are strongly encouraged by its rapidly broadening acceptance, particularly by patients, as an endorsement that validates TruFUSE's potential. With experienced management and systems in place to serve a much larger segment of the medical and healthcare community, both here and abroad, we are looking forward to the challenge of growing TruFUSE into a major surgical solution in the coming months."

TruFUSE is used to treat a variety of back problems, including augmentation of other procedures, for any location from C2-C3 to L5-S1. Compared to many existing methods, TruFUSE is generally less invasive, less destructive, less complicated, less expensive and subjects the patients to relatively minimal risk. It is also one of the few surgical options that can supplement or stand alone without precluding other options.

For more information on TruFUSE, please visit the Web site at http://www.trufuse.com or call (813) 318-0565 ext. 216.


'/>"/>
SOURCE Orthopedic Development Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India - Favored Orthopedics Surgery Destination
2. MDCT Compared to Digital Radiography in Orthopedic Patients
3. Drug Eluting Nanostructured Coatings Enable Targeted Drug Therapy for Orthopedic Patients
4. Developmental, neurologic problems common in extremely preterm infants
5. Cancer drugs in development nearly doubled since 1995
6. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
7. Role of zinc in development
8. Particulate matter affects lung development
9. Fossil teeth and human development
10. High development costs hinder entry of cancer super drugs into the market
11. Fireflies help speed development of new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The Workgroup for ... health IT to create efficiencies in healthcare information exchange and a trusted advisor to ... their latest industry white paper, entitled Barriers to Adoption of the ERA and ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... for solutions to their neck and back pain with a reputable physician in ... Allegion Spine Institute , formerly known as Nevada Spine Clinic was founded by ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... of the annual PAINWeek National Conference. On October 7, at the Hilton Providence, ... and exciting program providing busy clinicians and allied healthcare practitioners with 6.0 hours ...
(Date:9/19/2017)... Boca Raton (PRWEB) , ... ... ... Booster, a memory-enhancing and cognitive health supplement developed by a neurosurgeon, has ... U.S. online retailers. , Daily Brain Booster is currently available on ...
(Date:9/19/2017)... ... 2017 , ... For decades doctors, nurses, and other healthcare providers have been ... factors and calculating their cardiovascular disease (CVD) risk in the next 10 years. ... predicted today: an estimated 10-year risk prediction! , Imagine if the weatherman says there ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Calif. , Sept. 7, 2017  For nearly two decades, New ... in the Assisted Reproduction Insurance industry. Today, New Life Agency announces a ... medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... Del. , Sept. 6, 2017 NeuroRx, a ... Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast ... its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 ... in a pivotal trial of this sequential therapy targeting patients ... depression. 1 ...
Breaking Medicine Technology: